Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409643 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,259
- Enrollment target
NCT00409643: Completed Phase 3 study, sponsored by Novartis.
NCT00409643 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,259 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00409643, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,259 participants
- Enrollment target
Study Summary
This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
Interventions
- DRUG valsartan
- DRUG amlodipine
- DRUG valsartan+amlodipine combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,259 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
What the finished NCT00409643 record still lists
NCT00409643 is an interventional study that assigns participants to a tested intervention. Its 1,259 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 3 interventions - of which valsartan is the first listed.
NCT00409643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00409643 about?
NCT00409643 is a clinical study titled "Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients". This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
What is the current status of trial NCT00409643?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,259 participants. The study started on 2004-01. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00409643?
The interventions under investigation include: valsartan (DRUG), amlodipine (DRUG), valsartan+amlodipine combination (DRUG).
Who is sponsoring clinical trial NCT00409643?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00409643's enrollment target sits among peer trials
1,259 205th of 2000 higher than 1,796 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia